Eli Lilly (LLY) said Friday that new results showed that 50% of patients with moderate-to-severe atopic dermatitis, or eczema, achieved completely clear skin at three years after receiving single monthly maintenance injection of Ebglyss.
The patients were among the Ebglyss week 16 responders from the monotherapy trials, the company said.
Eli Lilly also said 87% achieved or maintained "almost-clear" skin at three years with Ebglyss based on data from a long-term extension study.
Ebglyss was approved by the US Food and Drug Administration in 2024 as a first-line monotherapy biologic treatment option after topical prescription therapies.
The company also said that based on additional studies, Ebglyss improved symptoms such as itch, skin pain and sleep loss due to itch.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。